Cover Image
市場調查報告書

Novabiotics Ltd- 產品平台檢討

Novabiotics Ltd - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253706
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
Novabiotics Ltd- 產品平台檢討 Novabiotics Ltd - Product Pipeline Review - 2015
出版日期: 2015年05月27日 內容資訊: 英文 29 Pages
簡介

Novabiotics Ltd是總公司設立於英國的生物科技企業。正在設計·開發解決未滿足需求的抗菌藥。使用透過抗菌胜肽平台與抗菌黏多醣體類的Lynovex這個化合物,來製造臨床階段抗菌藥。

本報告提供Novabiotics Ltd的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Novabiotics Ltd的基本資料

  • Novabiotics Ltd概要
  • 主要資訊
  • 企業資料

Novabiotics Ltd:R&D概要

  • 主要的治療範圍

Novabiotics Ltd:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Novabiotics Ltd:開發中產品概況

  • 臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
    • 第Ⅰ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Novabiotics Ltd:藥物簡介

  • cysteamine IR
  • NP-213
  • NP-339
  • NP-432
  • Synthetic Peptide for Acne Vulgaris
  • Synthetic Peptide for Polymicrobial Infections

Novabiotics Ltd:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Novabiotics Ltd:最近的開發平台資訊

Novabiotics Ltd:開發暫停中的計劃

Novabiotics Ltd:企業理念

Novabiotics Ltd:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07110CDB

Summary

Global Markets Direct's, 'Novabiotics Ltd - Product Pipeline Review - 2015', provides an overview of the Novabiotics Ltd's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Novabiotics Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Novabiotics Ltd including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Novabiotics Ltd's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Novabiotics Ltd's pipeline products

Reasons to buy

  • Evaluate Novabiotics Ltd's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Novabiotics Ltd in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Novabiotics Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Novabiotics Ltd and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Novabiotics Ltd
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Novabiotics Ltd and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Novabiotics Ltd Snapshot
    • Novabiotics Ltd Overview
    • Key Information
    • Key Facts
  • Novabiotics Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Novabiotics Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Novabiotics Ltd - Pipeline Products Glance
    • Novabiotics Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Novabiotics Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Novabiotics Ltd - Drug Profiles
    • cysteamine IR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NP-213
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NP-339
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NP-432
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide for Acne Vulgaris
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide for Polymicrobial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Novabiotics Ltd - Pipeline Analysis
    • Novabiotics Ltd - Pipeline Products by Target
    • Novabiotics Ltd - Pipeline Products by Route of Administration
    • Novabiotics Ltd - Pipeline Products by Molecule Type
    • Novabiotics Ltd - Pipeline Products by Mechanism of Action
  • Novabiotics Ltd - Recent Pipeline Updates
  • Novabiotics Ltd - Dormant Projects
  • Novabiotics Ltd - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Novabiotics Ltd, Key Information
  • Novabiotics Ltd, Key Facts
  • Novabiotics Ltd - Pipeline by Indication, 2015
  • Novabiotics Ltd - Pipeline by Stage of Development, 2015
  • Novabiotics Ltd - Monotherapy Products in Pipeline, 2015
  • Novabiotics Ltd - Phase II, 2015
  • Novabiotics Ltd - Phase I, 2015
  • Novabiotics Ltd - Preclinical, 2015
  • Novabiotics Ltd - Discovery, 2015
  • Novabiotics Ltd - Pipeline by Target, 2015
  • Novabiotics Ltd - Pipeline by Route of Administration, 2015
  • Novabiotics Ltd - Pipeline by Molecule Type, 2015
  • Novabiotics Ltd - Pipeline Products by Mechanism of Action, 2015
  • Novabiotics Ltd - Recent Pipeline Updates, 2015
  • Novabiotics Ltd - Dormant Developmental Projects,2015
  • Novabiotics Ltd, Subsidiaries

List of Figures

  • Novabiotics Ltd - Pipeline by Top 10 Indication, 2015
  • Novabiotics Ltd - Pipeline by Stage of Development, 2015
  • Novabiotics Ltd - Monotherapy Products in Pipeline, 2015
  • Novabiotics Ltd - Pipeline by Top 10 Target, 2015
  • Novabiotics Ltd - Pipeline by Top 10 Route of Administration, 2015
  • Novabiotics Ltd - Pipeline by Top 10 Molecule Type, 2015
  • Novabiotics Ltd - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top